ArticleJournal of lipid research2012
Psoriasis alters HDL composition and cholesterol efflux capacity.
Article in Journal of lipid research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 94 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
94 citing papers in PubMed, 168 citations in OpenAlex.
- Metabolic Complications in Autoimmune and Autoinflammatory Diseases: Pathophysiology, Clinical Implications, and Therapeutic Perspectives.Journal of clinical medicine · 2026Review
- The comparison of acute phase proteins in experimentally induced canine acute pancreatitis.BMC veterinary research · 2026Article
- Cardiovascular Disease and Psoriasis.Dermatology and therapy · 2026Review
- Exploring the role of gelsolin and high-density lipoproteins in autoimmune diseases: spotlight on rheumatoid arthritis and systemic lupus erythematosus.Oxford open immunology · 2026Review
- Serum Amyloid A (SAA) and Its Interaction with High-Density Lipoprotein Cholesterol (HDL-C): A Comprehensive Review.International journal of molecular sciences · 2025Review
- Characterization of intestinal microbiota in patients with psoriasis combined with metabolic syndrome.Molecular and cellular biochemistry · 2025Article
- Early Risk Prediction for Biologic Therapy in Psoriasis Using Machine Learning Models Based on Routine Health Records.Journal of clinical medicine · 2025Article
- High-density lipoproteins. Part 2. Impact of disease states on functionality.American journal of preventive cardiology · 2025Article
- Predictive Modeling of the Risk of Hyperglycemia in Psoriasis Patients Using Machine Learning: A Multicenter Retrospective Study.Clinical, cosmetic and investigational dermatology · 2025Article
- Association between neutrophil-to-high-density lipoprotein cholesterol ratio (NHR) and psoriasis risk: a nationally representative cross-sectional study.Frontiers in immunology · 2025Article
- Emerging Biomarkers and Determinants of Lipoprotein Profiles to Predict CVD Risk: Implications for Precision Nutrition.Nutrients · 2024Review
- High-Density Lipoprotein Metabolism and Function in Cardiovascular Diseases: What about Aging and Diet Effects?Nutrients · 2024Review
- Non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio associated with psoriasis: a cross-sectional study.Frontiers in medicine · 2024Article
- Unraveling the Pleiotropic Role of High-Density Lipoproteins (HDLs) in Autoimmune Rheumatic Diseases.International journal of rheumatology · 2024Review
- Association Between Non-HDL to HDL Cholesterol Ratio (NHHR) and Psoriasis in Adults: A Cross-Sectional Study Using 2009-2014 Data.Clinical, cosmetic and investigational dermatology · 2024Article
- A Current Update on the Role of HDL-Based Nanomedicine in Targeting Macrophages in Cardiovascular Disease.Pharmaceutics · 2023Review
- Article
- HDL Functions-Current Status and Future Perspectives.Biomolecules · 2023Review
- The relationship between blood lipid and risk of psoriasis: univariable and multivariable Mendelian randomization analysis.Frontiers in immunology · 2023Article
- Effects of Antirheumatic Treatment on Cell Cholesterol Efflux and Loading Capacity of Serum Lipoproteins in Spondylarthropathies.Journal of clinical medicine · 2022Article
34 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
Psoriasis, a chronic inflammatory skin disease, has been linked to increased myocardial infarction and stroke. Functional impairment of HDL may contribute to the excess cardiovascular mortality of psoriatic patients. However, data available regarding the impact of psoriasis on HDL composition and function are limited. HDL from psoriasis patients and healthy controls was isolated by ultracentrifugation and shotgun proteomics, and biochemical methods were used to monitor changed HDL composition. We observed a significant reduction in apoA-I levels of HDL from psoriatic patients, whereas levels of apoA-II and proteins involved in acute-phase response, immune response, and endopeptidase/protease inhibition were increased. Psoriatic HDL contained reduced phospholipid and cholesterol. With regard to function, these compositional alterations impaired the ability of psoriatic HDL to promote cholesterol efflux from macrophages. Importantly, HDL-cholesterol efflux capability negatively correlated with psoriasis area and severity index. We observed that control HDL, as well as psoriatic HDL, inhibited dihydrorhodamine (DHR) oxidation to a similar extent, suggesting that the anti-oxidative activity of psoriatic HDL is not significantly altered. Our observations suggest that the compositional alterations observed in psoriatic HDL reflect a shift to a pro-inflammatory profile that impairs cholesterol efflux capacity of HDL and may provide a link between psoriasis and cardiovascular disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.